NCT00268983 - Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

September 30, 2009

Study Completion Date

June 30, 2013

Conditions

Lymphoma, Non-Hodgkin

Interventions

BIOLOGICAL

Tositumomab and Iodine I 131 Tositumomab

"Dosimetric dose: 450 mg Tositumomab infused over 1 hour followed by 5 mCi I 131 Tositumomab infused over 20 minutes~Therapeutic dose: 450 mg Tositumomab infused over 1 hour followed by Individualized mCi activity of I 131 Tositumomab (35 mg) infused over 20 minutes."

BIOLOGICAL

Rituximab

Rituximab 375 mg/m2 given as an IV infusion once weekly for four weeks.

Trial Locations (3)

69495

GSK Investigational Site, Pierre-Bénite

99362

GSK Investigational Site, Walla Walla

Unknown

GSK Investigational Site, Manchester